Clinical Trials Logo

HER2-positive Breast Cancer clinical trials

View clinical trials related to HER2-positive Breast Cancer.

Filter by:

NCT ID: NCT04609540 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

Start date: January 1, 2021
Phase:
Study type: Observational

To explore the real world data of trastuzumab Combined With Trastuzumab And Chemotherapy in China, and to explore the relationship between progression free survival and treatment pattern.

NCT ID: NCT04337658 Not yet recruiting - Clinical trials for HER2-positive Breast Cancer

Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer

FAVOR
Start date: July 1, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effectiveness of anti-HER2 therapy plus Fulvestrant or Capecitabine in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 positive (HER2+), non-visceral metastases, stage IV breast cancer.

NCT ID: NCT04236310 Not yet recruiting - Breast Cancer Clinical Trials

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

Start date: January 15, 2020
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of the SHR6390 in combination with anastrozole, pyrotinib, and trastuzumab in patients with ER-positive, HER2-positive breast cancer in the neoadjuvant setting.

NCT ID: NCT04225858 Not yet recruiting - Breast Cancer Clinical Trials

Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy

ASICS
Start date: January 2020
Phase: N/A
Study type: Interventional

This study evaluates whether SLNB can safely be omitted in breast cancer patients with HER2+ or TN tumors who achieve a radiological complete response on MRI after neoadjuvant systemic therapy

NCT ID: NCT04158856 Not yet recruiting - Clinical trials for HER2-positive Breast Cancer

Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer

SHERO
Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial aims to study the efficacy and safety of adjuvant Pyrotinib plus trastuzumab in patients with tumors <8mm, node-negative, HER2-positive breast cancer.

NCT ID: NCT04088110 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Start date: November 2019
Phase: Phase 2
Study type: Interventional

This study is a single-arm, open-label, phase II study, comparing the efficacy and safety of pyrotinib plus trastuzumab and aromatase inhibitors, in the treatment of HR (hormone receptor)+/HER2 (human epidermal growth factor receptor 2) + MBC and inoperable LABC patients.

NCT ID: NCT04034823 Not yet recruiting - Clinical trials for HER2-positive Breast Cancer

KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer

Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

This is an open-label, single arm phase II trial to evaluate the efficacy, safety and tolerability of KN035 in combination with trastuzumab and docetaxel. Eligible patient will be enrolled and receive protocol defined therapies until progressive disease, unacceptable toxicity or withdrawal of informed consent. Tumor assessment will be performed according to RECIST 1.1 criteria.

NCT ID: NCT03947242 Not yet recruiting - Clinical trials for HER2 Positive Breast Cancer

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

Start date: June 1, 2019
Phase: N/A
Study type: Interventional

This study is a single-arm, prospective, open label clinical study for evaluating the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus Vinorelbine given as neoadjuvant treatment in Trastuzumab-refractory HER2 positive early stage or locally advanced breast cancer.

NCT ID: NCT03919253 Not yet recruiting - Clinical trials for HER2-positive Breast Cancer

Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study

Start date: April 30, 2019
Phase: Phase 2
Study type: Interventional

This clinical trial aim to evaluate the efficacy and safety of Pyrotinib in combination with nab-paclitaxel in patients with HER2-positive advanced breast cancer.

NCT ID: NCT03910712 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC

Pyrotinib
Start date: June 1, 2019
Phase: Phase 2
Study type: Interventional

This study is a randomized, open-label, phase II study, comparing the efficacy and safety of trastuzumab plus aromatase inhibitors, with or without pyrotinib, in the treatment of HR (hormone receptor)+/HER2 (human epidermal growth factor receptor 2) + MBC and inoperable LABC patients.